CLL Clinical Trial
Official title:
A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR) to therapy and the secondary endpoints will assess the safety and tolerability of the regimen, the impact of the treatment on progression free, treatment free, overall survival, and pharmacokinetics of ofatumumab. Patients will receive allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis.
Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR) to therapy and the secondary endpoints will assess the safety and tolerability of the regimen, the impact of the treatment on progression free, treatment free, overall survival, and pharmacokinetics of ofatumumab. Cycles 1-3 will be administered without scheduled interruption every 28 days for a total of 12 weeks of therapy. Patients will receive allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis. Blood glucose levels will be monitored immediately after HDMP infusion by finger stick glucometry. Two months following completion of treatment a response assessment will occur per iwCLL guidelines. The treatment will be administered as outpatient, and each cycle will be four weeks in duration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02229422 -
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01862445 -
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
|
||
| Completed |
NCT00535873 -
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
|
Phase 2 | |
| Withdrawn |
NCT03639324 -
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
|
Phase 1 | |
| Recruiting |
NCT05517265 -
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
|
||
| Recruiting |
NCT03868722 -
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04640909 -
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients
|
N/A | |
| Recruiting |
NCT05610228 -
Study of the Metabolism in the Lymphatic Niche of CLL
|
||
| Completed |
NCT01168921 -
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
| Withdrawn |
NCT05209308 -
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
|
Phase 2 | |
| Completed |
NCT00792077 -
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
|
Phase 2 | |
| Recruiting |
NCT06073821 -
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
| Recruiting |
NCT05246345 -
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
|
||
| Terminated |
NCT01532635 -
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
|
Phase 2 | |
| Completed |
NCT01703364 -
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
|
Phase 1/Phase 2 | |
| Terminated |
NCT03572634 -
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
|
Phase 1/Phase 2 | |
| Completed |
NCT03231579 -
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
|
||
| Completed |
NCT00636909 -
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT03524235 -
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
|
Phase 1 |